Why are GTS Chemical plc Hldg (+17%), Stanley Gibbons Group plc (-9%) and Redx Pharma plc (-10%) among today’s major movers?

Do major share price moves make these 3 stocks buys or sells? GTS Chemical plc Hldg (LON: GTS), Stanley Gibbons Group plc (LON: SGI) and Redx Pharma (LON: REDX)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m taking a look at three companies that are among the major movers on the London stock market today.

A very important development

Shares in GTS Chemical (LSE: GTS) have soared by around 17% today after it announced that it has received a certificate of registration from the American Petroleum Institute for conformance with the API Specification Q1.

This specification should further establish GTS’s brands, which in turn could attract more distributors and differentiate the company from its competitors. And with its being received for the quality management on nine of GTS’s products — including the core business divisions of ammonium sulphite, ammonium bisulfite and lubricating oil — it could prove to be a very important development for the company.

Looking ahead, GTS is forecast to post a fall in earnings in the current year of 6%. While this could hurt investor sentiment in the short run, the speciality chemicals company is due to increase its bottom line by 13% next year. This puts it on a forward price to earnings (P/E) ratio of just 3.9, which indicates that its shares are cheap and could be due for an upward rerating over the medium to long term.

Disappointing performance 

Also among today’s major movers is Stanley Gibbons (LSE: SGI), with the antiques and stamp collector posting a fall in its share price of around 9%. Given the company’s woes during the course of the year, this is perhaps unsurprising since investor sentiment is now rather weak. In fact, Stanley Gibbons’ shares have fallen by 84% since the turn of the year and there could be more pain to come. That’s because the company is set to endure a challenging period, with profitability forecast to come under pressure in the next financial year.

While Stanley Gibbons has the potential to turn its disappointing performance around, its risk/reward ratio seems to be relatively unappealing. That’s especially the case since there are a number of other smaller companies that are on the cusp of improved financial performance and which offer good value for money at the present time.

In a stronger position

Meanwhile, shares in Redx Pharma (LSE: REDX) have been down by as much as 10% today despite the drug development company having released no significant news flow. Of course, Redx recently conducted a £10m placing and the proceeds are set to be used to progress the company’s drug pipeline and to also further develop Redx’s other assets in immune-oncology, infection and immunology. And with the net proceeds strengthening the company’s balance sheet, Redx seems to be in a stronger position after the placing.

Clearly, Redx’s share price performance since the start of the year has been very poor. Its valuation has declined by around 55% and while it has significant long term potential, it may prudent for risk averse investors to look for greater stability and consistency elsewhere in the health care space.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »